Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14044920 | 1.00 | CTSS (0.45) | CTSSCTSKCACNA1BTACR1DRD2 | |
| SCHEMBL29582289 | 1.00 | CTSS (0.45) | CTSSCTSKCACNA1BTACR1DRD2 | |
| SCHEMBL10217306 | 0.89 | CTSK (0.46) | CTSSCTSKCACNA1BTACR1DRD2 | |
| SCHEMBL14044925 | 0.89 | CTSK (0.46) | CTSSCTSKCACNA1BTACR1DRD2 | |
| SCHEMBL8622009 | 0.89 | CTSS (0.39) | CTSSCTSKCACNA1BTACR1ATM | |
| SCHEMBL22805380 | 0.88 | CTSS (0.44) | CTSSCTSKCACNA1BTACR1DRD2 | |
| SCHEMBL28080125 | 0.87 | ALOX12 (0.40) | CTSSCTSKATMCTSLCTSB | |
| SCHEMBL3447780 | 0.86 | CACNA1B (0.47) | CTSSCTSKCACNA1BTACR1DRD2 | |
| SCHEMBL27603568 | 0.86 | CTSA (0.51) | CACNA1BPOLB | |
| SCHEMBL4883355 | 0.86 | CTSA (0.51) | CACNA1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2390250-B1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SK CHEMICALS CO LTD (KR) | 2015-08-12 | — | — | EP | disclosed |
| EP-2390250-B1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SK CHEMICALS CO LTD (KR) | 2015-08-12 | — | — | EP | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| EP-2390250-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Sk Chemicals Co., Ltd. (KR) | 2011-11-30 | — | — | EP | disclosed |
| EP-2390250-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Sk Chemicals Co., Ltd. (KR) | 2011-11-30 | — | — | EP | disclosed |
| WO-2011062437-A2 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS, MANUFACTURING METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 에스케이케미칼주식회사 (KR) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | CTSS 2349/4885CTSK 1275/4885CACNA1B 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.